Large size trial has been recommended with a cocktail of c-Kit+ CPCs and bone marrow derived stem cells to reduce infarct size and restore cardiac function after MI.27 Since the engraftment of transplanted cells remains low in most of the clinical trials so far, the potential benefits could be due to paracrine effect as opposed to transdifferentiation of injected cells into cardiomyocytes.28 Might it be possible to study the constituents of the paracrine mediators to repair heart instead of cell replacement therapy? The gene discussed is KIT; the disease is myocardial infarction.